AMRN AMARIN CORP PLC

Nasdaq www.amarincorp.com


$ 19.96 $ 0.65 (3.36 %)    

Wednesday, 15-Oct-2025 19:07:04 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 19.97
$ 19.25
$ 18.89 x 5
$ 19.97 x 1
$ 19.17 - $ 20.00
$ 7.08 - $ 20.43
70,463
na
nm
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet...

 amarin-to-present-icosapent-ethyl-eicosapentaenoic-acid-data-at-canadian-cardiovascular-congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company commi...

 reported-saturday-amarins-reduce-it-analyses-show-icosapent-ethyl-cuts-hospitalizations-by-9-and-lowers-cardiovascular-risk-in-high-risk-patients

2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High...

 amarin-to-present-new-data-on-icosapent-ethyls-cardioprotective-effects-at-esc-2025-highlighting-inflammation-and-oxidation-mechanisms

Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congres...

 amarin-corp-q2-adj-eps-004-beats-017-estimate-sales-72740m-beat-53786m-estimate

Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.17) b...

 goldman-sachs-maintains-sell-on-amarin-corp-raises-price-target-to-12

Goldman Sachs analyst Paul Choi maintains Amarin Corp (NASDAQ:AMRN) with a Sell and raises the price target from $7 to $12.

 amarin-shares-surge-after-175m-european-licensing-deal-for-heart-drug-vazkepa

Amarin Corporation (NASDAQ: AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license a...

 amarin-lands-massive-european-commercialization-deal-for-heart-drug-vazkepa-stock-surges

Amarin signs $175 million Vazkepa deal with Recordati, plans global restructuring and targets $70 million in cost cuts to impro...

Core News & Articles
Market-Moving News for June 24th
06/24/2025 11:16:06

INM: 102% | InMed shares are trading higher after the company announced preclinical data showing INM-901 reduced neuroinflammat...

 amarin-strikes-175m-deal-with-recordati-to-expand-heart-drug-vazkepa-across-59-european-countries

Amarin Corporation (NASDAQ:AMRN) today announced that the Company has entered into an exclusive long-term license and supply ag...

 amarin-corp-q1-adj-eps-002-beats-057-estimate-sales-4202m-miss-5075m-estimate

Amarin Corp (NASDAQ:AMRN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.57) b...

 amarin-regains-compliance-with-nasdaq-minimum-bid-price-requirement-nasdaq-compliance-follows-ads-ratio-change-to-secure-companys-public-listing

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing ---- Amarin Remains Focused on Maximizing ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION